MEI Pharma Inc - Asset Resilience Ratio
MEI Pharma Inc (MEIP) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MEIP working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how MEI Pharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MEIP total assets.
Liquid Assets Composition Over Time
This chart breaks down MEI Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read MEI Pharma Inc (MEIP) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: MEI Pharma Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
MEI Pharma Inc Industry Peers by Asset Resilience Ratio
Compare MEI Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for MEI Pharma Inc (2005–2025)
The table below shows the annual Asset Resilience Ratio data for MEI Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.00% | $0.00 | $18.29 Million | -- |
| 2024-06-30 | 83.72% | $34.64 Million | $41.38 Million | +14.37pp |
| 2023-06-30 | 69.35% | $83.79 Million | $120.81 Million | -7.97pp |
| 2022-06-30 | 77.32% | $137.51 Million | $177.84 Million | -5.90pp |
| 2021-06-30 | 83.22% | $144.88 Million | $174.10 Million | +2.02pp |
| 2020-06-30 | 81.20% | $170.30 Million | $209.73 Million | +2.69pp |
| 2019-06-30 | 78.51% | $64.90 Million | $82.66 Million | -6.94pp |
| 2018-06-30 | 85.45% | $89.43 Million | $104.66 Million | +4.48pp |
| 2017-06-30 | 80.98% | $45.11 Million | $55.70 Million | +6.60pp |
| 2016-06-30 | 74.38% | $35.08 Million | $47.16 Million | +4.79pp |
| 2015-06-30 | 69.59% | $45.06 Million | $64.75 Million | -0.72pp |
| 2014-06-30 | 70.30% | $35.02 Million | $49.81 Million | -- |
| 2013-06-30 | 0.00% | $0.00 | $36.55 Million | -- |
| 2012-06-30 | 0.00% | $0.00 | $6.37 Million | -- |
| 2005-06-30 | 51.64% | $10.00 Million | $19.36 Million | -- |
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, … Read more